We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device for transapical access. Survival at thirty days was 85.1% with a cardiovascular death rate of 4.8%. No strokes were observed during this period. Average gradient reduction was highly significant, (40.4 to 8.1 mmHg, p <0.001), as well as the effective aortic orifice increase, (0.8 to 1.7 cm2). There were no severe paravalvular aortic regurgitation after implantation.
Conclusion: This record, that assessed 2nd generation JenaValve device for transapical access, showed excellent safety and efficacy results.
Stephan Ensminger, MD, PHD.
2013-05-22
Original title: First results of the JUPITER registry on long-term performance and safetyof the transapical JenaValve.
